Edwards Lifesciences Corp

Company Profile

Edwards Lifesciences Corp had its IPO on 2000-03-27 under the ticker symbol EW.

The company operates in the Healthcare sector and Medical Devices industry. Edwards Lifesciences Corp has a staff strength of 17,300 employees.

Stock update

Shares of Edwards Lifesciences Corp opened at $74.47 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $73.06 - $74.95, and closed at $73.37.

This is a -2% slip from the previous day's closing price.

A total volume of 3,237,409 shares were traded at the close of the day’s session.

In the last one week, shares of Edwards Lifesciences Corp have slipped by -3.94%.

Edwards Lifesciences Corp's Key Ratios

Edwards Lifesciences Corp has a market cap of $52.10 billion, indicating a price to book ratio of 7.5391 and a price to sales ratio of 8.4778.

In the last 12-months Edwards Lifesciences Corp’s revenue was $5.50 billion with a gross profit of $4.30 billion and an EBITDA of $1.92 billion. The EBITDA ratio measures Edwards Lifesciences Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Edwards Lifesciences Corp’s operating margin was 32.39% while its return on assets stood at 13.05% with a return of equity of 25.01%.

In Q1, Edwards Lifesciences Corp’s quarterly earnings growth was a negative -5.1% while revenue growth was a positive 8.8%.

Edwards Lifesciences Corp’s PE and PEG Ratio

Forward PE

30.1205

Trailing PE

35.2213

PEG

3.0653

Its diluted EPS in the last 12-months stands at $2.44 per share while it has a forward price to earnings multiple of 30.1205 and a PEG multiple of 3.0653. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Edwards Lifesciences Corp’s profitability.

Edwards Lifesciences Corp stock is trading at a EV to sales ratio of 8.5433 and a EV to EBITDA ratio of 23.1882. Its price to sales ratio in the trailing 12-months stood at 8.4778.

Edwards Lifesciences Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$8.65 billion

Total Liabilities

$1.08 billion

Operating Cash Flow

$500000.00

Capital Expenditure

$61.50 million

Dividend Payout Ratio

0%

Edwards Lifesciences Corp ended 2024 with $8.65 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $8.65 billion while shareholder equity stood at $5.98 billion.

Edwards Lifesciences Corp ended 2024 with $0 in deferred long-term liabilities, $1.08 billion in other current liabilities, 647100000.00 in common stock, $7.93 billion in retained earnings and $1.31 billion in goodwill. Its cash balance stood at $872.50 million and cash and short-term investments were $1.25 billion. The company’s total short-term debt was $25,100,000 while long-term debt stood at $596.50 million.

Edwards Lifesciences Corp’s total current assets stands at $3.26 billion while long-term investments were $1.07 billion and short-term investments were $381.70 million. Its net receivables were $779.30 million compared to accounts payable of $180.80 million and inventory worth $914.30 million.

In 2024, Edwards Lifesciences Corp's operating cash flow was $500000.00 while its capital expenditure stood at $61.50 million.

Comparatively, Edwards Lifesciences Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$73.37

52-Week High

$107.92

52-Week Low

$67.13

Analyst Target Price

$94

Edwards Lifesciences Corp stock is currently trading at $73.37 per share. It touched a 52-week high of $107.92 and a 52-week low of $107.92. Analysts tracking the stock have a 12-month average target price of $94.

Its 50-day moving average was $82.71 and 200-day moving average was $81.69 The short ratio stood at 3.66 indicating a short percent outstanding of 0%.

Around 83.8% of the company’s stock are held by insiders while 8723.4% are held by institutions.